Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT03500328
NA

Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

Sponsor: Johns Hopkins University

View on ClinicalTrials.gov

Summary

FDA-approved multiple sclerosis (MS) disease-modifying therapies (DMTs) target the relapsing phase of MS but have minimal impact once the progressive phase has begun. It is unclear if, in the relapsing phase, there is an advantage of early aggressive therapy with respect to preventing long-term disability. The infectious risks and other complications associated with higher-efficacy treatments highlight the need to quantify their effectiveness in preventing disability. The TRaditional versus Early Aggressive Therapy for MS (TREAT-MS) trial is a pragmatic, randomized controlled trial that has two primary aims: 1) to evaluate, jointly and independently among patients deemed at higher risk vs. lower risk for disability accumulation, whether an "early aggressive" therapy approach, versus starting with a traditional, first-line therapy, influences the intermediate-term risk of disability, and 2) to evaluate if, among patients deemed at lower risk for disability who start on first-line MS therapies but experience breakthrough disease, those who switch to a higher-efficacy versus a new first-line therapy have different intermediate-term risk of disability.

Official title: A Pragmatic Trial to Evaluate the Intermediate-term Effects of Early, Aggressive Versus Escalation Therapy in People With Multiple Sclerosis

Key Details

Gender

All

Age Range

18 Years - 60 Years

Study Type

INTERVENTIONAL

Enrollment

900

Start Date

2018-05-02

Completion Date

2026-08-01

Last Updated

2025-10-14

Healthy Volunteers

No

Interventions

OTHER

Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq

Early Aggressive Therapy

OTHER

Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod

Traditional Therapy

Locations (47)

University of Alabama at Birmingham

Birmingham, Alabama, United States

The University of South Alabama

Mobile, Alabama, United States

St. Joseph's Hospital & Medical Center - Barrow Neurological Institute

Phoenix, Arizona, United States

CommonSpirit Health Research Institute

Carmichael, California, United States

Cedars-Sinai Medical Center

Los Angeles, California, United States

University of California, Los Angeles

Los Angeles, California, United States

University of California, San Diego

San Diego, California, United States

University of California, San Francisco

San Francisco, California, United States

Christiana Care Health Services, Inc.

Newark, Delaware, United States

Georgetown University

Washington D.C., District of Columbia, United States

University of Florida

Gainesville, Florida, United States

University of Miami

Miami, Florida, United States

University of South Florida Health

Tampa, Florida, United States

Rush University Medical Center

Chicago, Illinois, United States

The University of Kansas Medical Center (KUMC)

Kansas City, Kansas, United States

Norton Neurology MS Services

Louisville, Kentucky, United States

University of Maryland, Baltimore

Baltimore, Maryland, United States

The Johns Hopkins Hospital

Baltimore, Maryland, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

University of Massachusetts Medical School

Worcester, Massachusetts, United States

University of Michigan

Ann Arbor, Michigan, United States

Wayne State University

Detroit, Michigan, United States

Mayo Clinic

Rochester, Minnesota, United States

Billings Clinic

Billings, Montana, United States

Advanced Neurology Specialists

Great Falls, Montana, United States

University of Nebraska Medical Center

Omaha, Nebraska, United States

Hackensack University Medical Center

Hackensack, New Jersey, United States

New York University School of Medicine

New York, New York, United States

Icahn School of Medicine at Mount Sinai

New York, New York, United States

Columbia University Medical Center

New York, New York, United States

University of Cincinnati

Cincinnati, Ohio, United States

OhioHealth Research Institute

Columbus, Ohio, United States

Oklahoma Medical Research Foundation

Oklahoma City, Oklahoma, United States

Providence Health and Services - Oregon

Portland, Oregon, United States

Geisinger Clinic

Danville, Pennsylvania, United States

Allegheny Health Network Research Institute

Pittsburgh, Pennsylvania, United States

Vanderbilt Comprehensive MS Center

Nashville, Tennessee, United States

Baylor Scott and White Health

Dallas, Texas, United States

University of Texas Southwestern Medical Center

Dallas, Texas, United States

Central Texas Neurology Consultants

Round Rock, Texas, United States

University of Utah

Salt Lake City, Utah, United States

The University of Vermont and State Agricultural College

Burlington, Vermont, United States

Blacksburg Neurology

Christiansburg, Virginia, United States

Neurology Consultants of Tidewater

Norfolk, Virginia, United States

Swedish Health Services

Seattle, Washington, United States

University of Washington

Seattle, Washington, United States

Medical College of Wisconsin

Milwaukee, Wisconsin, United States